Skip to main navigation Skip to search Skip to main content

Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?

Research output: Contribution to journalScientific reviewpeer-review

9 Scopus citations

Abstract

Breast cancer is the most prevalent cancer in women and presently, the breast cancer survivors are an important group of women that faced the several consequences of estrogen deficiency, which is especially common in women after chemotherapy. The most bothersome is the vasomotor symptoms, which are effectively relieved by hormonal therapy (HT). Also, the increased risk of osteoporosis and coronary artery disease is major problem to be resolved in pos of maintaining a good quality of life. Fearing cancer recurrence, most physicians do not offer HT to women with a history of breast cancer. Over this issue reviews the available evidence of the use of HT and tibolone in women treated for breast cancer.
Original languageAmerican English
Pages (from-to)10-15
Number of pages6
JournalGynecological Endocrinology
Volume33
Issue number1
DOIs
StatePublished - 2 Jan 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Breast cancer
  • cancer survivors
  • estrogen–progestin therapy
  • hormone therapy
  • menopausal symptoms
  • tibolone

Fingerprint

Dive into the research topics of 'Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?'. Together they form a unique fingerprint.

Cite this